Recent changes
Anti-C5 Antibody, C5 iRNA Dosing Regimens, Complement Diseases
Anti-C5 Antibody, C5 iRNA Dosing Regimens, Complement Diseases
Immunogenic Compositions for SARS-CoV-2 Vaccines Using MHC Class II Peptides
USPTO published patent application US20260097115A1 for immunogenic compositions containing MHC class II-binding peptides derived from SARS-CoV-2 translation products. The application covers vaccine compositions and methods for treating and preventing COVID-19. Inventors include researchers from Broad Institute and affiliated institutions.
Novel Anti-Asporin Antibody Targets Fibrotic Disease Including Idiopathic Pulmonary Fibrosis
USPTO published patent application US20260098083A1 disclosing a novel antibody binding specifically to Asporin protein for predicting onset and treating fibrotic diseases, including idiopathic pulmonary fibrosis. Inventors are Hogeun Yoon and Soo-Yeon Park. The application was filed on September 20, 2023.
PD-1 Monoclonal Antibody Patent Application for Cancer Treatment
The USPTO published patent application US20260098092A1 for monoclonal antibodies targeting human programmed cell death protein 1 (PD-1) and methods for treating cancer using said antibodies and antigen-binding fragments. The application was filed October 4, 2023, naming seven inventors including Trairak Pisitkun and colleagues. Pharmaceutical and biotech companies developing PD-1/PD-L1 pathway cancer immunotherapies should monitor for this application's progression to grant.
Anti-TMPRSS6 Monoclonal Antibodies and Therapeutic Uses
USPTO published patent application US20260098084A1 disclosing fully human anti-TMPRSS6 monoclonal antibodies for treating diseases associated with TMPRSS6. Inventors include Harvey Chin, Sarah J. Hatsell, Heinrich Emil Lob, Andrew J. Murphy, William Olson, Kei Saotome, and Bojie Zhang, with application number 19323318 filed September 9, 2025.
Composition Improves Salt Tolerance in Plants
Composition Improves Salt Tolerance in Plants
Surface-Modified Viral Particles and Modular Viral Particles Patent Application
USPTO published patent application US20260098280A1 for surface-modified viral particles and modular viral particles (anellovectors and anelloVLPs) filed December 8, 2025. The application names five inventors including Simon Delagrave, Kurt Adam Swanson, and Noah Robert Cohen. CPC classifications include C12N 15/86 and C07K 14/005.
NAVROGEN Fc-Engineered Monoclonal Antibodies Targeting ICAM-1/CD54 for Cancer Treatment
USPTO published patent application US20260098858A1 for NAVROGEN, INC. covering Fc-engineered monoclonal antibodies with CH3 region modifications designed to reduce ICAM-1/CD54 binding, improving immune-effector activity and antibody drug conjugate killing for cancer and inflammatory disease treatment.
TACI Antibody and Use Thereof for Detecting Free Drug Levels
The USPTO published patent application US20260098866A1 covering a human TACI (B lymphocyte stimulator receptor) antibody with high specificity and affinity, along with methods for detecting free TACI or TACI-Fc fusion protein drug levels in patients. The invention enables monitoring of drug absorption and therapeutic efficacy in patients with autoimmune diseases.
Methods for Rule-based Genome Design
USPTO published patent application US20260100251A1 for computer-implemented methods of rule-based genome design. The application covers systems receiving known genome data and allele lists, generating alternative gene sequences, and scoring each sequence using a weighted combination of multiple rules, constraints, or parameters. Inventors include George M. Church and Nili Ostrov.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
693 changes in last 7 days
Latest high priority updates
140 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.